Samsung Electronics
Search results
Samsung Bioepis is a biopharmaceutical company focused on increasing patient access to high-quality medicines through the development of biosimilars. SAMSUNG BIOEPIS Contact Us
Samsung Bioepis is a biopharmaceutical company dedicated to accelerating access to biologic medicines by bringing high-quality, clinically proven biosimilars to patients who need them. Our mission is reflected in our name, bio-epis; literally meaning life (“bio”) and science (“episteme”) in Greek.
Apr 20, 2022 · • Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary. • First payment completed funded through paid in capital. • Accelerated growth expected in biosimilars and future novel therapeutics R&D.
1 day ago · For the period, Samsung Bioepis achieved (PDF) sales of 530 South Korean won ($384 million), which was a 107% year-over-year increase and a 75% sequential boost.
3 days ago · INCHEON, South Korea, July 22, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the Biologics License Application ...
3 days ago · Having already taken leadership of the eculizumab biosimilar market in Europe, Samsung Bioepis ’ Soliris copycat will now be available in the U.S. The South Korean biopharma announced Monday the FDA has approved Epysqli for a rare, life-threatening disease of the blood.. Samsung’s Epysqli is a biosimilar to AstraZeneca’s Soliris (eculizumab), picked up by the company in its $39 billion acquisition of Alexion in 2020. Soliris generated $3.15 billion in 2023 global sales for AstraZeneca ...
Jul 11, 2024 · Samsung C&T, a major shareholder of Samsung Biologics which has Samsung Bioepis as a 100% owned subsidiary, has chosen bio/healthcare areas as a sustainable growth engine and the investment in the Flagship Pioneering Fund VIII perfectly matches our mid-term growth strategy,” said Jaywoo Kim, executive vice president, Samsung C&T Corporation.
Apr 20, 2022 · Samsung Biologics has now fully acquired Samsung Bioepis, as a wholly owned subsidiary. First payment completed funded through paid-in capital. Accelerated growth expected in biosimilars and...
Sep 20, 2021 · Pursuant to a global license agreement entered into with Genentech, Samsung Bioepis and Biogen will have freedom to market SB11 in the United States as of June 2022, i.e., before expiration of...
Aug 17, 2022 · Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology, hematology,...
